Glial Cell Derived Neurotrophic Factor (Gdnf) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a potent neurotrophic factor discovered in 1973 and initially characterized for its ability to promote the survival and differentiation of dopaminergic neurons in the substantia nigra[1]. GDNF belongs to the GDNF family ligands (GFLs) which also includes neurturin (NRTN), artemin (ARTN), persephin (PSPN), and the recently identified GDNF-like factors. These proteins share a common structural fold and signal through a unique receptor system involving the GFRα family of co-receptors.
GDNF is the most potent neurotrophic factor known for supporting dopaminergic neuron survival and has been investigated extensively as a potential disease-modifying therapy for Parkinson's disease. Unlike other neurotrophins like BDNF, GDNF signals through a distinct mechanism involving GPI-anchored co-receptors and the RET receptor tyrosine kinase[2].
Human GDNF is synthesized as a 211-amino acid preproprotein that undergoes:
- N-terminal signal peptide cleavage (1-19)
- Proteolytic processing to generate the mature, active homodimer
- Secretion as a disulfide-linked homodimer
The crystal structure of GDNF reveals a unique fold:
- N-terminal heptapeptide: Critical for receptor binding
- Hairpin loop: Stabilizes dimer interface
- Core cysteine knot motif: Provides structural stability
- Two antiparallel β-strands: Form the dimerization interface
The active form is a disulfide-linked homodimer (approximately 30 kDa) with each monomer containing seven conserved cysteine residues that form three disulfide bonds[3].
GDNF signals through a unique bipartite receptor system:
- GFRα1: GPI-anchored co-receptor that binds GDNF with high affinity
- RET: Receptor tyrosine kinase that transduces the signal intracellularly
The binding sequence is: GDNF → GFRα1 → RET → intracellular signaling cascades
¶ Neuronal Survival and Development
GDNF is essential for the development and maintenance of several neuronal populations:
- Promotes survival of substantia nigra pars compacta (SNc) dopamine neurons
- Supports neurite outgrowth and arborization
- Maintains tyrosine hydroxylase (TH) expression
- Protects against 6-OHDA and MPTP toxicity (see [Parkinson's Disease Mechanisms--TEMP--/mechanisms)--FIX--)
- Supports spinal cord motor neuron survival
- Promotes motor axon guidance during development
- Protective in ALS models
- Critical for development of the enteric nervous system
- Supports gut motility neurons
- Deficiency leads to Hirschsprung disease-like phenotype
GDNF activation of RET triggers multiple downstream pathways:
- PI3K/Akt: Pro-survival signaling
- RAS/ERK: Neurite outgrowth and differentiation
- PLCγ: Calcium signaling and synaptic plasticity
GDNF is produced by astrocytes and Schwann cells, providing trophic support to neurons:
- Astrocytic GDNF supports neuronal homeostasis
- Schwann cell GDNF promotes peripheral nerve regeneration
GDNF has shown neuroprotective effects in multiple PD models:
- Dopamine neuron protection: Prevents 6-OHDA-induced death of SNc neurons
- Behavioral rescue: Improves motor function in parkinsonian animals
- Neurochemical restoration: Restores dopamine levels and turnover
- Anti-inflammatory effects: Modulates microglial activation
Multiple clinical trials have evaluated GDNF delivery in PD patients:
| Trial |
Delivery Method |
Outcome |
| Kordower et al. (2000) |
AAV-GDNf to putamen |
Positive, improved UPDRS |
| Gill et al. (2003) |
Intraputamenal infusion |
Positive, improved motor scores |
| Lang et al. (2006) |
Intraputamenal infusion |
Negative, no significant benefit |
| Bartus et al. (2011) |
AAV-GDNF (CERE-120) |
Negative, trial halted |
The mixed results have been attributed to:
- Delivery method limitations
- Patient selection criteria
- Dose and distribution challenges
- Need for continuous rather than one-time delivery
New strategies to overcome delivery challenges:
- AAV vectors: Gene therapy approaches using adeno-associated viruses
- Blood-brain barrier penetrating peptides: Engineering GDNF fusion proteins
- Cell encapsulation: Using encapsulated cell devices for controlled release
- Small molecule mimics: Developing small molecules that activate GFRα1/RET
- AAV-GDNF: Using AAV vector to deliver GDNF gene directly to brain
- CERE-120: AAV2-GDNF construct, completed Phase 1/2 trials
- ProSavin: AAV vector encoding GDNF family member neurturin
- Continuous infusion: Intraputamenal delivery devices
- Encapsulated cells: Cell therapy approaches using GDNF-secreting cells
- Fusion proteins: Engineering GDNF with BBB-penetrating domains
- GFRα1 agonists: Developing small molecules that activate the GFRα1/RET complex
- RET agonists: Direct RET tyrosine kinase agonists in development
- BDNF/GF mimetics: Combined approaches targeting multiple pathways
¶ Drug Candidates in Development
| Drug/Approach |
Mechanism |
Stage |
Status |
| AAV-GDNF gene therapy |
GDNF overexpression |
Phase 1/2 |
Completed, mixed results |
| Cere-120 (AAV2-GDNF) |
Gene therapy |
Phase 2 |
Discontinued |
| Cell encapsulation |
Controlled GDNF release |
Preclinical |
Proof-of-concept |
| Small molecule GFRα1 agonists |
Receptor activation |
Discovery |
Lead optimization |
| GDNF fusion proteins |
BBB-penetrant GDNF |
Preclinical |
In development |
- [GDNF Gene--TEMP--/genes)--FIX--: The gene encoding GDNF
- [Parkinson's Disease--TEMP--/diseases)--FIX--: Primary therapeutic target
- [Dopaminergic Neurons--TEMP--/cell-types)--FIX--: Target cell population
- [GFRAL Gene--TEMP--/genes)--FIX--: GFRα-like co-receptor
- [Neurturin (NRTN)--TEMP--/proteins)--FIX--: Related GDNF family member
- [Neurotrophic Factor Therapy--TEMP--/treatments)--FIX--: Therapeutic approaches
- [Parkinson's Disease Mechanisms--TEMP--/mechanisms)--FIX--: Disease context
The study of Glial Cell Derived Neurotrophic Factor (Gdnf) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [/diseases/parkinsons--TEMP--/diseases)--FIX--
- [/mechanisms/alpha-synuclein--TEMP--/mechanisms)--FIX--
- [/mechanisms/app-processing--TEMP--/mechanisms)--FIX--
- [/mechanisms/amyloid-aggregation--TEMP--/mechanisms)--FIX--
- [/mechanisms/microglia-neuroinflammation--TEMP--/mechanisms)--FIX--
- Lin LF, et al. (1993). "GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons". Science 260(5111):1130-1132. PMID:8493557
- Airaksinen MS, Saarma M. (2002). "The GDNF family: signalling, biological functions and therapeutic value". Nat Rev Neurosci 3(5):383-394. PMID:11988777
- Eigenbrot C, et al. (1997). "Crystal structure of the neurotrophic factor GDNF and the binding characteristics of its receptor GFRα1". J Biol Chem 272(52):33078-33084. PMID:9407087
- Kordower JH, et al. (2000). "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease". Science 290(5492):767-773. PMID:11052933
- Gill SS, et al. (2003). "Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease". Nat Med 9(5):589-595. PMID:12669033
- Bartus RT, et al. (2013). "Reflections on the last and the next generation of gene therapy for Parkinson's disease". Neurobiol Dis 48:219-225. PMID:23041681